CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER (CRPC) explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER (CRPC) trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER (CRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill shows promise against Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IDE574, which targets specific enzymes that help cancer cells grow. It is for people with advanced solid tumors (like lung, prostate, or colorectal cancer) or a type of breast cancer called ER+, HER2-. The trial has two parts: one where IDE574 i…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Phase: PHASE1, PHASE2 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated May 26, 2026 02:18 UTC
-
Radioactive antibody targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
Phase: PHASE1, PHASE2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated May 26, 2026 02:16 UTC